Altavista Wealth Management Inc. Has $3.42 Million Stake in Allergan plc (AGN)

Altavista Wealth Management Inc. grew its position in Allergan plc (NYSE:AGN) by 2.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,967 shares of the company’s stock after buying an additional 471 shares during the quarter. Allergan accounts for about 1.3% of Altavista Wealth Management Inc.’s portfolio, making the stock its 27th largest holding. Altavista Wealth Management Inc.’s holdings in Allergan were worth $3,422,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Boltwood Capital Management grew its holdings in shares of Allergan by 5.6% during the 3rd quarter. Boltwood Capital Management now owns 5,081 shares of the company’s stock valued at $967,000 after purchasing an additional 270 shares during the last quarter. Parkside Investments LLC grew its holdings in shares of Allergan by 1.8% during the 2nd quarter. Parkside Investments LLC now owns 15,845 shares of the company’s stock valued at $2,830,000 after purchasing an additional 275 shares during the last quarter. Avestar Capital LLC grew its holdings in shares of Allergan by 25.1% during the 2nd quarter. Avestar Capital LLC now owns 1,483 shares of the company’s stock valued at $230,000 after purchasing an additional 298 shares during the last quarter. New Jersey Better Educational Savings Trust grew its holdings in shares of Allergan by 9.4% during the 2nd quarter. New Jersey Better Educational Savings Trust now owns 3,500 shares of the company’s stock valued at $584,000 after purchasing an additional 300 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Allergan by 34.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,233 shares of the company’s stock valued at $205,000 after purchasing an additional 319 shares during the last quarter. Institutional investors own 78.48% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. ValuEngine raised shares of Allergan from a “strong sell” rating to a “sell” rating in a report on Friday, September 21st. TheStreet raised shares of Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. Cowen set a $255.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Wednesday, October 17th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $180.00 target price on shares of Allergan in a report on Friday, September 14th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $209.18.

In other news, CFO Matthew M. Walsh purchased 1,000 shares of the company’s stock in a transaction dated Friday, November 16th. The shares were purchased at an average price of $157.00 per share, for a total transaction of $157,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Joseph H. Boccuzi purchased 900 shares of the company’s stock in a transaction dated Thursday, August 30th. The stock was purchased at an average price of $190.59 per share, for a total transaction of $171,531.00. The disclosure for this purchase can be found here. Insiders bought a total of 11,900 shares of company stock worth $2,234,931 in the last 90 days. Corporate insiders own 0.36% of the company’s stock.

AGN opened at $153.61 on Monday. Allergan plc has a fifty-two week low of $142.81 and a fifty-two week high of $197.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.78 and a current ratio of 0.92. The company has a market cap of $51.81 billion, a price-to-earnings ratio of 9.40, a price-to-earnings-growth ratio of 1.19 and a beta of 1.31.

Allergan (NYSE:AGN) last posted its earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.04 by $0.21. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.15 EPS. Equities research analysts forecast that Allergan plc will post 16.49 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Tuesday, November 13th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.87%. Allergan’s dividend payout ratio (DPR) is currently 17.61%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.wkrb13.com/2018/11/26/altavista-wealth-management-inc-has-3-42-million-stake-in-allergan-plc-agn.html.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Further Reading: What is insider trading?

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply